Focosi et al., 2021 - Google Patents
SARS-CoV-2 variants: a synopsis of in vitro efficacy data of convalescent plasma, currently marketed vaccines, and monoclonal antibodiesFocosi et al., 2021
View HTML- Document ID
- 15129086467335114960
- Author
- Focosi D
- Tuccori M
- Baj A
- Maggi F
- Publication year
- Publication venue
- Viruses
External Links
Snippet
We summarize here in vitro evidences of efficacy for convalescent plasma, currently approved vaccines and monoclonal antibodies against SARS-CoV-2 variants of concern (VOC: B. 1.1. 7, B. 1.351, P. 1, and B. 1.617. 2), variants of interest (VOI: B. 1.427/B. 1.429, P …
- 241001678559 COVID-19 virus 0 title abstract description 84
Classifications
-
- G—PHYSICS
- G06—COMPUTING; CALCULATING; COUNTING
- G06Q—DATA PROCESSING SYSTEMS OR METHODS, SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL, SUPERVISORY OR FORECASTING PURPOSES; SYSTEMS OR METHODS SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL, SUPERVISORY OR FORECASTING PURPOSES, NOT OTHERWISE PROVIDED FOR
- G06Q50/00—Systems or methods specially adapted for a specific business sector, e.g. utilities or tourism
- G06Q50/10—Services
- G06Q50/22—Health care, e.g. hospitals; Social work
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Focosi et al. | SARS-CoV-2 variants: a synopsis of in vitro efficacy data of convalescent plasma, currently marketed vaccines, and monoclonal antibodies | |
| Pormohammad et al. | Efficacy and safety of COVID-19 vaccines: a systematic review and meta-analysis of randomized clinical trials | |
| Doroftei et al. | Mini-review discussing the reliability and efficiency of COVID-19 vaccines | |
| Jahn et al. | Humoral response to SARS-CoV-2-vaccination with BNT162b2 (Pfizer-BioNTech) in patients on hemodialysis | |
| Kanokudom et al. | Safety and immunogenicity of the third booster dose with inactivated, viral vector, and mRNA COVID-19 vaccines in fully immunized healthy adults with inactivated vaccine | |
| Tan | Norovirus vaccines: current clinical development and challenges | |
| Focosi et al. | Analysis of immune escape variants from antibody-based therapeutics against COVID-19: a systematic review | |
| Lopez et al. | Live attenuated African swine fever viruses as ideal tools to dissect the mechanisms involved in cross-protection | |
| Ruan et al. | COVID-19 vaccination in patients with myasthenia gravis: a single-center case series | |
| Spinardi et al. | Hybrid immunity to SARS-CoV-2 from infection and vaccination—evidence synthesis and implications for new COVID-19 vaccines | |
| Guzmán-Martínez et al. | IgG antibodies generation and side effects caused by Ad5-nCoV vaccine (CanSino Biologics) and BNT162b2 vaccine (Pfizer/BioNTech) among Mexican population | |
| Zhou et al. | Immune imprinting and implications for COVID-19 | |
| Pratama et al. | Effectiveness of COVID-19 vaccines against SARS-CoV-2 Omicron variant (B. 1.1. 529): a systematic review with meta-analysis and meta-regression | |
| Matkowska-Kocjan et al. | The COVID-19 mRNA BNT163b2 vaccine was well tolerated and highly immunogenic in young adults in long follow-up after haematopoietic stem cell transplantation | |
| Zhang et al. | Immunogenicity of a heterologous prime-boost COVID-19 vaccination with mRNA and inactivated virus vaccines compared with homologous vaccination strategy against SARS-CoV-2 variants | |
| Zhang et al. | A heterologous V-01 or variant-matched bivalent V-01D-351 booster following primary series of inactivated vaccine enhances the neutralizing capacity against SARS-CoV-2 Delta and Omicron strains | |
| Touabi et al. | Mechanisms of rhinovirus neutralisation by antibodies | |
| Roth et al. | Optimised non-coding regions of mRNA SARS-CoV-2 vaccine CV2CoV improves homologous and heterologous neutralising antibody responses | |
| Reeg et al. | SARS-CoV-2-specific T cell responses in immunocompromised individuals with cancer, HIV or solid organ transplants | |
| Yang et al. | Developing an effective peptide-based vaccine for COVID-19: Preliminary studies in mice models | |
| Poniedziałek et al. | Relationship between humoral response in COVID-19 and seasonal influenza vaccination | |
| Luangdilok et al. | Immunogenicity after a third COVID-19 mRNA booster in solid cancer patients who previously received the primary heterologous CoronaVac/ChAdOx1 vaccine | |
| Muñoz-Valle et al. | Efficacy and safety of heterologous booster vaccination after Ad5-nCoV (CanSino Biologics) vaccine: a preliminary descriptive study | |
| Benedicto-Matambo et al. | Leveraging beneficial off-target effects of live-attenuated rotavirus vaccines | |
| Abdelhafiz et al. | Sinopharm’s BBIBP-CorV vaccine and ChAdOx1 nCoV-19 vaccine are associated with a comparable immune response against SARS-CoV-2 |